» Articles » PMID: 25543218

Low Concentration of Dezocine in Combination With Morphine Enhance the Postoperative Analgesia for Thoracotomy

Overview
Date 2014 Dec 29
PMID 25543218
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: When morphine and dezocine are mixed together, the clinical interactions with analgesic effects and adverse events remain unknown. The authors aimed to investigate the efficacy of low concentrations of dezocine in combination with morphine for postoperative pain.

Design: A prospective, randomized, double-blinded clinical trial.

Setting: Cancer Institute and Hospital, National Cancer Center, China.

Participants: Sixty patients undergoing thoracotomy were randomized into 3 groups to investigate the analgesic efficacy of different ratios of morphine and dezocine.

Interventions: The morphine group (Group M) received morphine (1 mg/mL) alone for patient-controlled analgesia (PCA); the morphine+dezocine 1 group (Group MD1) received morphine (1 mg/mL) combined with dezocine (0.05 mg/mL) at a ratio of 20:1 for PCA; the morphine+dezocine 2 group (Group MD2) received morphine (1 mg/mL) combined with dezocine (0.1 mg/mL) at a ratio of 10:1 for PCA. Cumulative morphine consumption, verbal rating scores (VRS), and adverse events were evaluated throughout a 48-hour postoperative period.

Measurements And Main Results: Cumulative morphine requirements were (1) statistically higher in Group M than in Group MD2 at 24 and 48 hours after surgery and (2) statistically higher in Group M than Group MD1 at 48 hours after surgery. Postoperative VRS for evaluating pain were similar among the 3 groups. The incidence of postoperative nausea and pruritus was statistically higher in Group M than in Groups MD1 and MD2. The incidence of dizziness was not significantly different among groups.

Conclusions: The combination of morphine and dezocine at the concentrations [morphine (mg/mL)]/[dezocine (mg/mL)] of 1/0.05 (ratio 20:1) and 1/0.1 (ratio 10:1) may enhance postoperative analgesia after thoracotomy.

Citing Articles

Dezocine inhibits cell proliferation, migration, and invasion by targeting CRABP2 in ovarian cancer.

Zhang C, Pan R, Ma S, Xu S, Wang B Open Med (Wars). 2022; 17(1):2052-2061.

PMID: 36568517 PMC: 9755696. DOI: 10.1515/med-2022-0541.


Efficacy of dezocine on preventing opioid-induced cough during general anaesthesia induction: a PRISMA-compliant systematic review and meta-analysis.

He L, Yao Y, Shao K, Zhao Y, Ma J BMJ Open. 2022; 12(4):e052142.

PMID: 35379614 PMC: 8981282. DOI: 10.1136/bmjopen-2021-052142.


Effects of Dezocine and Sufentanil on Th1/Th2 Balance in Breast Cancer Patients Undergoing Surgery.

Hu X, Luo B, Wu Q, Chen Q, Lu P, Huang J Drug Des Devel Ther. 2021; 15:4925-4938.

PMID: 34880602 PMC: 8648097. DOI: 10.2147/DDDT.S326891.


Dezocine as a potent analgesic: overview of its pharmacological characterization.

Ye R, Jiang S, Xu X, Lu Y, Wang Y, Liu J Acta Pharmacol Sin. 2021; 43(7):1646-1657.

PMID: 34737418 PMC: 9253008. DOI: 10.1038/s41401-021-00790-6.


Effects of dezocine on morphine tolerance and opioid receptor expression in a rat model of bone cancer pain.

Wu L, Dong Y, Zhu Q, Zhang B, Ai B, Yan T BMC Cancer. 2021; 21(1):1128.

PMID: 34670518 PMC: 8529774. DOI: 10.1186/s12885-021-08850-0.